Cardiol Therapeutics (CRDL) Common Equity (2020 - 2026)
Cardiol Therapeutics' (CRDL) quarterly Common Equity came in at $17.6 million in Q1 2026, up 43.99% YoY from $12.3 million in Q1 2025, and up 37.67% on a QoQ basis from $12.8 million in Q4 2025.
Cardiol Therapeutics (CRDL) Common Equity (2020 - 2026) Analysis & Trends
Cardiol Therapeutics (CRDL) has 7 years of Common Equity data on file, last reported at $17.6 million in Q1 2026.
- Quarterly Common Equity rose 43.99% year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (up 43.99% YoY) and the FY2025 annual result came in at $12.8 million, down 27.58% from the prior year.
- Common Equity grew to $17.6 million in Q1 2026, from $12.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $54.6 million in Q1 2022 to a low of $6.9 million in Q3 2025.
- A 5-year average of $23.9 million and a median of $17.7 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity surged 94.72% — and 2024, when it sank 70.6%.
- Tracing CRDL's Common Equity over 5 years: stood at $38.5 million in 2022, then sank by 46.05% to $20.7 million in 2023, then declined by 14.68% to $17.7 million in 2024, then decreased by 27.58% to $12.8 million in 2025, then jumped by 37.67% to $17.6 million in 2026.
- The last three Common Equity figures came in at $17.6 million (Q1 2026), $12.8 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Cardiol Therapeutics | 215.50 Mn | 196.65 Mn | - | 17.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.65 Mn |
| Dec 31, 2025 | 12.82 Mn |
| Sep 30, 2025 | 6.95 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Mar 31, 2025 | 12.26 Mn |
| Dec 31, 2024 | 17.70 Mn |
| Sep 30, 2024 | 7.65 Mn |
| Jun 30, 2024 | 11.23 Mn |
| Mar 31, 2024 | 14.89 Mn |
| Dec 31, 2023 | 20.75 Mn |
| Sep 30, 2023 | 26.01 Mn |
| Jun 30, 2023 | 28.85 Mn |
| Mar 31, 2023 | 33.70 Mn |
| Dec 31, 2022 | 38.46 Mn |
| Sep 30, 2022 | 44.99 Mn |
| Jun 30, 2022 | 49.30 Mn |
| Mar 31, 2022 | 54.64 Mn |
| Dec 31, 2021 | 60.48 Mn |
| Sep 30, 2021 | 23.11 Mn |
| Jun 30, 2021 | 69.58 Mn |